1958
 
 - The Company was incorporated as a private company to take over the
 business previously carried on by the brand office of Parke-Davis &
 Co.
 Ltd., U.S.A.  On 16th May, 1961, the Company became a deemed public
 company by virtue of the provisions of Section 43A of the Companies
 Act.  The Company Manufacture Pharmaceutical formulations, bulk
 drugs
 and chemicals.
 
 1970
 
 - Parke-Davis & Co., U.S.A., was acquired by Warner-Lambert Co.,
 U.S.A., and is now a wholly owned subsidiary of the latter.
 Warner-Lambert Co., is a major worldwide provider of health care and
 consumer products.
 
 - The basic drugs and formulations manufactured by the Company are
 based on know-how provided by Parke-Davis & Co., U.S.A., in terms of
 the Technical Assistance Agreement dated 22nd December, 1958.
 
 1974
 
 - 8,750 shares are held by Parke-Davis & Co., Detroit, U.S.A., and
 its
 nominees.
 
 1975
 
 - 10,500 bonus shares issued in prop. 1:1.
 
 - By the amendment made to the Articles of Association of the
 Company
 in 1975, the Company became a public limited company.
 
 1978
 
 - 12,600 bonus shares issued in prop. 3:5.
 
 1982
 
 - The Company has entered into three Registered User Agreements
 dated
 29th August, 4th June, 1971 and 24th October, 1979, the registration
 of
 the last two of which is pending.
                                                                      
                                                                       
                                                                       
                                                                       
                                                                       
                                                                       
                                                                       
                                                                      
 
 - During July-August, Parke-Davis & Co., Detroit, U.S.A., offered
 for
 sale to resident Indian nationals 14,56,000 No. of equity shares of
 Rs
 10 each of the Company at a premium of Rs 4 per share out of its
 holdings as follows: 15,000 shares to UTI, 50,000 shares to
 employees
 of the Company on the basis of firm allotment and 13,91,000 shares
 to
 the public.
 
 1985
 
 - Warner Hindustan Ltd. (WHL) was amalgamated with Parke-Davis
 (India)
 Ltd. (PDL) with effect from 1st December.  Pursuant to the scheme of
 Amalgamation, PDL allotted during 1987-89, 41,73,624 new equity
 shares
 to the shareholders of WHL without payment in cash in the ratio of 7
 shares of PDL for every 5 shares of WHL held.
 
 1990
 
 - 45,20,174 bonus shares issued in prop. 3:5.
 
 1992
 
 - The Company laid emphasis on the main areas of R&D efforts as set
 out
 with a view to introducing new products and improving existing
 products
 and developing new packaging.
 
 - The Company has a full-fledged R&D Division and maintains
 continuous
 interaction with Warner-Lambert Company, U.S.A. which provides
 necessary advice and technical assistance for production of
 Pharmaceuticals, Bulk Drugs and Consumer Products.
 
 1994
 
 - During the year under review, sales of Chloramphenicol products
 were
 adversely affected due to the continued dumping of L-Base (drug
 intermediate for Choloramphenicol) by China at considerably lower
 prices.
 
 1995
 
 - The Company has developed with the help of film manufacturers, and
 used, reverse printed polyester laminated with Heat Sealable
 Pearlised
 Biaxially oriented Polypropylene.
 
 1996
 
 - During the year, the Company has entered into non-competition
 agreement in respect of Confectionery Products business with
 Warner-Lambert Co., U.S.A. and effective 14th August, 1995, the
 Company
 has agreed not to carry on the said business in competition with
 Warner-Lambert Co. or any subsidiary or affiliate thereof. 
 
 1997
 
 - During the year, the company launched several line extensions like
 LOPIDOD (Gemfibrozil 900mg) and DILANTIN, a lower strength
 formulation
 of its leading anti-epileptic, Dilantin.
 
 - Also, the company launched ATPARK a cardiovascular product in
 25mg,
 50mg and 100mg formulations.  The company also relaunched Ferradol a
 food supplement aimed at children for catering to their energy
 needs.
 
 - Parke-Davis India, the partly-owned subsidiary of the US-based
 pharmaceuticals giant.
 
 - Parke-Davis (India) in the near future is unlikely to get five
 major
 products which Glaxo Wellcome worldwide has transferred to the
 company's US collaborator, Warner-Lambert.
 
 1998
 
 - Parke-Davis is a 40 per cent subsidiary of American multinational
 Warner Lambert.
 
 - Crisil has assigned a P1+ rating to the Rs 19.35-crore commercial
 paper programme of Parke Davis (India) Ltd.
 
 - Parke- Davis' parent, Warner-Lambert Co., is one of the world's
 bigger pharmaceutical and consumer product companies.
 
 - Parke-Davis launched a line extension of the antacid last year,
 Gelusil Plus.
 
 1999
 
 - The company's new brand Calcal (calcium carbonate plus vitamin D3)
 had received an encouraging response from doctors.
 
 - Parke Davis India Ltd, a subsidiary of the US pharma giant Warner
 Lambert.
 
 2000
 
 - The Company signed a MoU with M/s. A-class Builders & Developers
 Pvt.
 Ltd. for the sale of its property admeasuring approx. 52000 sq.mtrs,
 situated at Saki Naka, Mumbai.
 
 - The Company has signed a Memorandum of Intended Transfer for the
 sale
 of its property at Saki Naka, Mumbai for an aggregate consideration
 of
 Rs 4930 lakhs.
 
 - The Company introduced Gelsil MPS in the over-the-counter product
 category.
 
 - The Company has informed that its foreign collaborators, viz.
 Warner-Lambert Co., Us, Parke, Davis & Co., US, who together hold 40
 per cent of the paid-up equity share capital of the company have
 merged
 into Pfizer Inc. USA group effective June 19.
 
 - The Company has launched its Benadryl cough formula in a PET
 bottle.
 
 - Crisil has reaffirmed the `P1+' rating assigned to the Rs
 26.8-crore
 commercial paper programme of Parke-Davis India Ltd.
 
 2002
 
 - M G Subramaniam appointed as Compliance Officer of Parke-Davis.
 
 -Parke Davis offers VRS at its Hyderabad Plant.
 
 --The operational merger between Pfizer and Parke-Davis has been
 completed and the legal merger is underway.
 
 2003
   
 -Supreme Court permits Parke-Davis(I) merger with Pfizer,The company
 will issue equity shares in the ratio of 9:4 Parke-Davis shareholders
 getting four shares in Pfizer for every nine shares they hold.